Pharmacokinetics of Etomidate in Patients with Different Degrees of Burn
-
摘要:
目的 研究依托咪酯在不同程度烧伤患者体内的药代动力学。 方法 选取行切痂植皮烧伤患者45例,按轻中重度烧伤分为A、B、C 3组,每组15例。45例患者开始以舒芬太尼TCI给药,TCI舒芬太尼15 min(Tt15)时开始静脉恒速泵注依托咪酯(0.4 mg/kg),2 min泵注结束,辅以罗库溴铵,右美托咪定,七氟烷麻醉维持,维持BIS值在40~60。在TCI开始后20、30、40、50、60、90 min及TCI停药时(停时)和TCI停药后1、3、5、8、10、20、30 min时间点采集动脉血2 mL,测定标本血浆中依托咪酯的Cm,计算药代动力学参数。 结果 C组的K31、CL1、CL3小于A组和B组(P < 0.05);C组的V3、T1/2r 大于A组和B 2组(P < 0.05)。A组和B组的K31、CL1、CL3、V3、T1/2r组间,差异无统计学意义(P > 0.05)。 结论 重度烧伤患者依托咪酯药代动力学参数中,K31变小、V3增加、CL1、CL3降低,T1/2r明显延长,可适当减少用药剂量。 Abstract:Objective To study the pharmacokinetics of etomidate in patients with varying degrees of burns. Methods 45 burn patients who underwent escharetomy and skin grafting, and they were divided into A.B.C three groups according to light, mooderate and severe burns. Anesthesia induction: All the 45 patients were given target controlled infusion of sufentanil (target blood concentration 0.4 ng/ml). Intravenous infusion of etomidate began after 15 minutes (Tt15), the dosage of etomidate was 0.4 mg/kg, and the pump infusion was set at the end of 2 minutes, and supplemented by rocuroniumto, dexmedetomidine and sevoflurane maintaining the BIS at 40~60. Before anesthesia (basis), starting TCI sufentanil 20, 30, 40, 50, 60, 90 min and stopping TCI sufentanil (Stop) and stopping TCI sufentanil 1, 3, 5, 8, 10, 20, 30 min.arterial blood were collected.Plasma concentration of etomidate was determined. Finally, the pharmacokinetic parameters of each group were calculated. Results Pharmacokinetic parameters of etomidate K31, CL1 and CL3 in group C were smaller than those in group A and group B, (P < 0.05). V3, T1/2r r of group C were greater than those of group A and B (P < 0.05). There was no significant difference between group A and group B in V3, K31. T1/2r, CL1 and CL3. (P > 0.05). Conclusion In patients with severe burns, when etomidate was used intraoperatively, K31 became smaller, V3 increased, CL1 and CL3 decreased, T1/2r was significantly prolonged, and pharmacological effects were enhanced, In clinical work, dosage can be appropriately reduced. -
Key words:
- Burn /
- Etomidate /
- Pharmacokinetics
-
表 1 一般情况(
$\bar x \pm s$ )Table 1. General information (
$\bar x \pm s$ )项目 A组(n = 15) B组(n = 15) C组(n = 15) 术前白蛋白(g/L) 39.8 ± 5.4* 36.7 ± 4.5* 29.8 ± 3.8 术前ALT(U/L) 33.8 ± 21.9* 34.0 ± 26.24* 117.8 ± 86.0 出血量(mL) 149 ± 89.1* 134 ± 56.4* 427 ± 189.2 与C组比较,*P < 0.05。 表 2 依托咪酯药代动力学参数(
$\bar x \pm s$ )Table 2. Pharmacokinetical parameters of Etomidate (
$\bar x \pm s$ )项目 A组(n = 15) B组(n = 15) C组(n = 15) T1/2α(min) 2.48 ± 0.83 2.29 ± 0.67 2.33 ± 0.52 T1/2β(min) 24.54 ± 2.62 25.50 ± 4.72 25.01 ± 5.37 T1/2r(min) 257.97 ± 51.11a 275.47 ± 40.92a 357.47 ± 60.5 V1(L) 4.92 ± 1.29 5.14 ± 1.04 4.87 ± 1.12 V2(L) 16.22 ± 3.12 14.52 ± 2.13 15.26 ± 2.11 V3(L) 117.11 ± 22.12* 114.20 ± 19.15* 141.61 ± 28.21 CL1(L/min) 1.41 ± 0.39* 1.37 ± 0.27* 1.09 ± 0.29 CL2(L/min) 1.07 ± 0.21 0.91 ± 0.17 0.99 ± 0.18 CL3(L/min) 0.97 ± 0.14* 0.89 ± 0.18* 0.68 ± 0.19 K10(min−1) 0.287 ± 0.014 0.266 ± 0.013 0.223 ± 0.043 K12(min−1) 0.271 ± 0.029 0.177 ± 0.016 0.172 ± 0.022 K21(min−1) 0.066 ± 0.004 0.065 ± 0.003 0.065 ± 0.017 K13(min−1) 0.197 ± 0.032 0.173 ± 0.033 0.139 ± 0.025 K31(min−1) 0.008 28 ± 0.002 9* 0.0079 ± 0.001 7* 0.004 81 ± 0.000 9 与C组比较,*P < 0.05。 -
[1] 夏照帆,胡晓燕,王光毅. 烧伤休克的发病机制和病理生理[J]. 中华损伤与修复杂志,2007,42(6):323-324. [2] Lehnhardt M,Jafari H J,Druecke D. A qualitative and quantitative analysis of protein loss in human burn wounds[J]. Burns,2005,31(2):159-167. doi: 10.1016/j.burns.2004.08.015 [3] Shuttler J O,Schwilden H,Stoeckel H. Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs:Etomidate as an example[J]. Eur J Anaesthesiol,1985,2(4):133-142. [4] De1Ruiter G,Popescu D T,de1Boer A G. Pharmacokinetics of etomidate in surgical patients[J]. Arch Int Pharmacodyn Ther,1981,249(2):180-188. [5] 任三姐,张马忠,王珊娟. 患者输注依托咪酯的群体药代动力学[J]. 中华麻醉学杂志,2013,33(5):573-575. doi: 10.3760/cma.j.issn.0254-1416.2013.05.014 [6] 宋金超. 梗阻性黄疸对依托咪酯药效动力学和药代动力学的影响[J]. 第二军医大学,2016,18(12):68-72. [7] Hvan Beem H,Manger F W,van Boxtel C. Etomidate anaesthesia in patients with cirrhosis of the liver:pharmacokinetic data[J]. Anaesthesia,1983,38(Supp1):61-62. [8] Zhang C,Xu Y,Gao P. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rat[J]. Intlmmun-opharmacol,2015,24(2):153-158. [9] Chen Q,Wei D. Human cytochrome P450 and personalized medicine[J]. Adv Exp Med Biol,2015,8(27):341-351. [10] Renton K W. Alteration of drug biotransformation and elimination During infection and inflammation[J]. Pharmacol Ther,2001,92(2-3):147-163. doi: 10.1016/S0163-7258(01)00165-6 [11] Morgan E T. Regulation of cytochromes P450 during inflammation and infection[J]. Drug Metab Rev,1997,29(4):1129-1188. doi: 10.3109/03602539709002246 [12] 缪文禹,贾金雪,秦金东,等. 依托咪酯在免疫性肝损伤中的药代动力学研究[J]. 临床麻醉学杂志,2016,32(1):65-68. [13] 李杨,郝纯澍,栾晓菲,等. LPS下调小鼠肝脏、肠道羧酸酯酶表达[J]. 现代生物医学进展,2010,10(6):1030-1033. [14] 张玲莉,彭燕. 急性肝损伤模型建立与血清生化指标相关性研究[J]. 中国药师,2015,18(9):1460-1463. doi: 10.3969/j.issn.1008-049X.2015.09.009 [15] 方之杨, 吴中立, 高学书. 烧伤理论与实践[M]. 沈阳: 辽宁科学技术出版社, 1988: 104-150.